Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|HPLC:||Shows Min ＞99% purity|
|H-NMR:||Consistent with structure|
|Description:||Monalizumab is a first-in-class immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab can be used in the study of head and neck squamous cell carcinoma (HNSCC).|
|Stability and Solubility Advice:||Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide.
We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials and used within 1 month. Avoid repeated freeze and thaw cycles. Storage conditions for some special products should refer to their storage details.